^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAY2666605

    i
    Other names: BAY2666605, BAY 2666605, BAY-2666605
    Associations

    News

    Trials
    Company:
    Bayer
    Drug class:
    SLFN12-PDE3A complex inducer
    Associations

    News

    Trials
    1year
    First-in-human dose escalation study of the first-in-class PDE3A-SLFN12 complex inducer BAY 2666605 in patients with advanced solid tumors co-expressing SLFN12 and PDE3A. (PubMed, Clin Cancer Res)
    Despite the decreased PDE3A enzymatic inhibition profile of BAY 2666605, the occurrence of thrombocytopenia in treated patients, an on-target effect of the compound, precluded the achievement of a therapeutic window, consequently leading to trial termination.
    P1 data • Journal • Metastases
    |
    PDE3A (Phosphodiesterase 3A)
    |
    PDE3A overexpression
    |
    BAY2666605
    1year
    Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12. (PubMed, ACS Med Chem Lett)
    More analogs were prepared and tested with the goal of increasing metabolic stability and decreasing PDE3 inhibition while maintaining the cellular activity of BRD9500. This led to the discovery of BAY 2666605, a compound optimized for clinical testing.
    Journal
    |
    PDE3A (Phosphodiesterase 3A)
    |
    BAY2666605
    over1year
    Velcrin molecular glues induce apoptosis in glioblastomas with high PDE3A and SLFN12 expression. (PubMed, Neurooncol Adv)
    We also determined that the velcrins BAY 2666605 and BRD3800 induce tumor regression in subcutaneous glioblastoma PDX models. Velcrins have antitumor activity in preclinical models of glioblastoma, warranting further investigation as potential therapeutic agents.
    Journal
    |
    PDE3A (Phosphodiesterase 3A) • BRD3 (Bromodomain Containing 3)
    |
    BAY2666605
    almost2years
    A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer (clinicaltrials.gov)
    P1, N=5, Terminated, Bayer | Completed --> Terminated; Due to the high probability of not achieving a therapeutic window and lack of evidence of sufficient clinical benefit.
    Trial termination • Metastases
    |
    PDE3A (Phosphodiesterase 3A)
    |
    BAY2666605
    over2years
    A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer (clinicaltrials.gov)
    P1, N=5, Completed, Bayer | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    PDE3A (Phosphodiesterase 3A)
    |
    BAY2666605
    almost3years
    A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Bayer | Trial completion date: Jun 2024 --> Mar 2023 | Trial primary completion date: Mar 2024 --> Nov 2022
    Trial completion date • Trial primary completion date • Metastases
    |
    PDE3A (Phosphodiesterase 3A)
    |
    BAY2666605
    almost3years
    A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into, Through and Out of the Body, the Maximum Amount That Can be Given and Its Action Against Tumors in Adult Participants With Skin Cancer That Has Spread to Other Parts of the Body and Other Types of Advanced Cancer (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Bayer | Recruiting --> Active, not recruiting | N=89 --> 5
    Enrollment closed • Enrollment change • Metastases
    |
    PDE3A (Phosphodiesterase 3A)
    |
    BAY2666605